Regulatory risk CVS Caremark faces ongoing antitrust, ERISA, and 340B-related legal scrutiny in 2025–2026, signaling a need for robust compliance, audit readiness, and transparent pricing practices. Sales opportunities exist in offering advanced compliance governance, risk assessment services, and trusted PBM transparency solutions to health plans and employers.

340B and pricing pressure Recent lawsuits alleging improper 340B funds handling and spread pricing highlight financial and reputational risk around pricing models. Potential to position value-based contracts, independent medical auditing, and pricing optimization tools that demonstrate compliant, ethical 340B utilization and measurable savings.

Biosimilar adoption push Caremark plans targeted formulary updates to increase biosimilar uptake, including FDA-interchangeable options. This creates opportunities to sell formulary analytics, real-time decision support, and clinician engagement programs to accelerate biosimilar adoption and manage payer transition costs.

Strategic partnerships Recent alliances with universities and Novo Nordisk indicate openness to preferred vendor arrangements and specialty drug management. Opportunities exist to propose specialty pharmacy workflow optimization, preferred pricing arrangements, and integrated care programs with biopharma and academic health systems.

Digital and analytics focus With advanced digital pharmacy tools, real-time insights, and analytics driving adherence and outcomes, there is demand for expanded data integration, member engagement platforms, and scalable analytics partnerships to further optimize spend, adherence, and clinical results.